ノースカロライナにおける非小細胞肺癌の臨床試験
ノースカロライナ内の拠点で、非小細胞肺癌に関する79件の研究が参加者を募集しています。
ノースカロライナ内の都市
公式研究テキスト（英語）
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- FirstHealth of the Carolinas- Speciality Center /ID# 272924, Pinehurst
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/05更新 · NCT06568939Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
- FirstHealth of the Carolinas-Moore Regional Hospital, Pinehurst
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/05更新 · NCT07388524Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Cone Health MedCenter Asheboro, Asheboro
- Cone Health Cancer Center at Alamance Regional, Burlington
- Wake Forest University at Clemmons, Clemmons
- 他8件
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/05更新 · NCT04267848A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Carolina Cancer Research Center, Wilson
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06270706A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/02更新 · NCT07293247The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Duke University, Durham
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/10/02更新 · NCT04585750A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Novant Health Weisiger Cancer Insititute ( Site 0266), Charlotte
- Novant Health Forsyth Medical Center ( Site 0166), Winston-Salem
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06623422Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #12, Durham
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/01更新 · NCT05176483A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
- Charles George VA Medical Center ( Site 3233), Asheville
- UNC Lineberger Comprehensive Cancer Center ( Site 3250), Chapel Hill
- WakeMed Raleigh Campus ( Site 3214), Raleigh
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07513376A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
- WakeMed Raleigh Campus ( Site 0144), Raleigh
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07554339Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Duke Cancer Center Cary, Cary
- Durham VA Medical Center, Durham
- Duke University Medical Center, Durham
- 他2件
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06498635A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
- Novant Health Pharmacy Oncology Specialists, Winston-Salem
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07361497A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
- Novant Health Pharmacy Oncology Specialists, Winston-Salem
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07361510Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
- Carolinas Medical Center, Charlotte
- Duke Cancer Center, Durham
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/30更新 · NCT06765109A Study of PHN-012 in Patients With Advanced Solid Tumors
- PHN-012-001 Site, Durham
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/29更新 · NCT07127874Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- UNC Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/29更新 · NCT06881784Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
- Levine Cancer Institute, Charlotte
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT04253964A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Messino Cancer Centers Asheville, Asheville
- Duke University Medical Center, Durham
- FirstHealth Cancer Center, Pinehurst
被験者募集中第3相
18歳〜100歳 · 全性別 · 2026/09/25更新 · NCT05920356Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- FirstHealth Cancer Center, Pinehurst
- FirstHealth Moore Regional Hospital, Pinehurst
- Carolina Cancer Research Center, Wilson
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07222566A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
- University of North Carolina at Chapel Hill, Chapel Hill
- FirstHealth of the Carolinas, Pinehurst
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06667908A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Atrium Health, Charlotte
- Regional Medical Oncology Center, Wilson
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06667076This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Brody School of Medicine at East Carolina University, Greenville
- ECU Health Medical Center, Greenville
- Carolina Cancer Research Center, Wilson
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06758401Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- FirstHealth of the Carolinas-Moore Regional Hospital, Pinehurst
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/24更新 · NCT03191149Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- WakeMed Raleigh Campus, Raleigh
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/24更新 · NCT06890598Pan-tumor MRD Study
- Carolina Oncology Specialists, Charlotte
- Southeastern Medical Oncology Center (SMOC), Goldsboro
- Regional Medical Oncology Center, Wilson
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/24更新 · NCT06605404Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
- Research Site, Greenville
- Research Site, Salisbury
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/23更新 · NCT06357533A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- East Carolina University, Greenville
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/23更新 · NCT06561386A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Local Institution - 0624, Asheville
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06875310Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer
- Atrium Health Levine Cancer, Charlotte
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT05696782Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
- Fletcher Hospital, Inc. dba AdventHealth Hendersonville, Hendersonville
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06712316A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
- Duke Cancer Center Durham, Durham
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07488676Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
- FirstHealth of the Carolinas, Inc., Pinehurst
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/21更新 · NCT06745882A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Research Site, Wilson
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/18更新 · NCT06692738Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- Carolina Biooncology Institute, Huntersville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/18更新 · NCT05267626Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Clinical Study Site, Chapel Hill
- Clinical Study Site, Durham
- Clinical Study Site, Pinehurst
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/18更新 · NCT06767514Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
- Levine Cancer Institute, Charlotte
- Durham VA Health Care System, Durham
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/17更新 · NCT07195695Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- Duke University School of Medicine, Durham
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/16更新 · NCT05786924Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Duke University Medical Center, Durham
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/16更新 · NCT04613596Effects of Infusion Timing on Treatment Response in Solid Tumors
- University of North Carolina at Chapel Hill, Department of Radiation Oncology, Chapel Hill
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/15更新 · NCT07630168Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
- FirstHealth Cancer Center, Pinehurst
- Carolina Cancer Research Center, Wilson
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/15更新 · NCT06899126ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。